TapImmune Inc. (TPIM.OB) Moves Forward with Testing of Cancer Vaccine
TapImmune Inc. (TPIM.OB) recently announced that an independent third-party research group published an article in the Journal of Investigative Dermatology confirming that a TapImmune (TAP) vaccine should be considered as a therapy for treating melanoma-based cancer. The National Cancer Institute has forecast that, within the next five years, cancer will be ranked as the number one cause of death of Americans. The company’s TAP vaccine against cancer helps the body move cancer makers to the surface of cells to allow a person’s body to detect and fight the cancerous cells. Initially developed at The University of British Columbia, the preclinical…